{"version":"1.0","provider_name":"Breakthrough T1D","provider_url":"https:\/\/breakthrought1d.eu\/nl","author_name":"ylt-admin","author_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/","title":"Pil voor minder insuline en minder schommelingen - Breakthrough T1D","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"lddx4Rxfkk\"><a href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\">Pil voor minder insuline en minder schommelingen<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/embed\/#?secret=lddx4Rxfkk\" width=\"600\" height=\"338\" title=\"&#8220;Pil voor minder insuline en minder schommelingen&#8221; &#8212; Breakthrough T1D\" data-secret=\"lddx4Rxfkk\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/breakthrought1d.eu\/nl\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Breakthrough T1D is een partnerschap aangegaan met Lexicon Pharmaceuticals, een bedrijf dat een nieuw medicijn, LX4211, heeft ontwikkeld. Samen staan de bedrijven aan de vooravond van de volgende klinische testfase waarin het medicijn samen met insuline wordt gebruikt bij mensen met Type 1 Diabetes. Het medicijn is een zogenaamde &#8216;inhibitor&#8217; van twee mechanismen die glucose [&hellip;]"}